1. Home
  2. KRUS vs ANL Comparison

KRUS vs ANL Comparison

Compare KRUS & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kura Sushi USA Inc.

KRUS

Kura Sushi USA Inc.

HOLD

Current Price

$46.46

Market Cap

650.6M

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$10.20

Market Cap

731.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRUS
ANL
Founded
2008
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
650.6M
731.6M
IPO Year
2019
2022

Fundamental Metrics

Financial Performance
Metric
KRUS
ANL
Price
$46.46
$10.20
Analyst Decision
Buy
Strong Buy
Analyst Count
9
1
Target Price
$81.11
$20.00
AVG Volume (30 Days)
374.4K
129.2K
Earning Date
04-07-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
79.75
N/A
EPS
N/A
N/A
Revenue
$282,763,000.00
N/A
Revenue This Year
$20.50
$36.02
Revenue Next Year
$20.68
N/A
P/E Ratio
N/A
N/A
Revenue Growth
18.88
N/A
52 Week Low
$42.62
$0.88
52 Week High
$95.98
$17.25

Technical Indicators

Market Signals
Indicator
KRUS
ANL
Relative Strength Index (RSI) 40.40 40.94
Support Level $42.81 $6.92
Resistance Level $58.75 $12.59
Average True Range (ATR) 2.98 1.15
MACD -0.49 -0.11
Stochastic Oscillator 24.98 26.07

Price Performance

Historical Comparison
KRUS
ANL

About KRUS Kura Sushi USA Inc.

Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: